Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00310089 · ClinicalTrials.gov registry record · NA
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
A NA study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT00310089: Completed NA study, sponsored by National Cancer Institute (NCI).
NCT00310089 is a NA study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00310089, a NA study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171 together with combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed and may kill more tumor cells. PURPOSE: This randomized clinical trial is studying how well giving AZD2171 together with combination chemotherapy works in treating women with locally advanced breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- BIOLOGICAL filgrastim
- BIOLOGICAL pegfilgrastim
- DRUG cediranib maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00310089
The ClinicalTrials.gov registry entry for NCT00310089 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00310089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00310089 about?
NCT00310089 is a clinical study titled "AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer". RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by ...
What is the current status of trial NCT00310089?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2006-01. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00310089?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), filgrastim (BIOLOGICAL), pegfilgrastim (BIOLOGICAL), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00310089?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.